Beigene Ltd (BGNE)

$149.38

+5.26

(+3.65%)▲

Live

Insights on Beigene Ltd

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 781.30M → 634.40M (in $), with an average decrease of 18.8% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 215.41M → -367.55M (in $), with an average decrease of 270.6% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 49.7% return, outperforming this stock by 91.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 240.7% return, outperforming this stock by 295.4%

Performance

  • $146.48
    $152.83
    $149.38
    downward going graph

    1.94%

    Downside

    Day's Volatility :4.16%

    Upside

    2.26%

    downward going graph
  • $126.97
    $266.67
    $149.38
    downward going graph

    15.0%

    Downside

    52 Weeks Volatility :52.39%

    Upside

    43.98%

    downward going graph

Returns

PeriodBeigene LtdSector (Health Care)Index (Russel 2000)
3 Months
-12.65%
1.7%
0.0%
6 Months
-13.43%
11.3%
0.0%
1 Year
-41.6%
5.4%
1.3%
3 Years
-55.57%
13.9%
-22.1%

Highlights

Market Capitalization
15.6B
Book Value
$33.83
Earnings Per Share (EPS)
-8.45
PEG Ratio
0.0
Wall Street Target Price
272.77
Profit Margin
-35.86%
Operating Margin TTM
-60.62%
Return On Assets TTM
-12.4%
Return On Equity TTM
-22.26%
Revenue TTM
2.5B
Revenue Per Share TTM
23.55
Quarterly Revenue Growth YOY
66.9%
Gross Profit TTM
-511.1M
EBITDA
-1.1B
Diluted Eps TTM
-8.45
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-8.62
EPS Estimate Next Year
-4.45
EPS Estimate Current Quarter
-3.85
EPS Estimate Next Quarter
-2.68

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Beigene Ltd(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
13
14
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 82.6%

Current $149.38
Target $272.77

Company Financials

FY18Y/Y Change
Revenue
198.2M
↓ 16.85%
Net Income
-673.8M
↑ 623.67%
Net Profit Margin
-339.91%
↓ 300.85%
FY19Y/Y Change
Revenue
428.2M
↑ 116.03%
Net Income
-950.6M
↑ 41.08%
Net Profit Margin
-221.99%
↑ 117.92%
FY20Y/Y Change
Revenue
308.9M
↓ 27.87%
Net Income
-1.6B
↑ 68.37%
Net Profit Margin
-518.18%
↓ 296.19%
FY21Y/Y Change
Revenue
1.2B
↑ 280.83%
Net Income
-1.4B
↓ 11.69%
Net Profit Margin
-120.15%
↑ 398.03%
FY22Y/Y Change
Revenue
1.4B
↑ 20.37%
Net Income
-2.0B
↑ 41.78%
Net Profit Margin
-141.52%
↓ 21.37%
FY23Y/Y Change
Revenue
2.5B
↑ 73.65%
Net Income
-881.7M
↓ 56.0%
Net Profit Margin
-35.86%
↑ 105.66%
Q3 FY22Q/Q Change
Revenue
387.6M
↑ 13.48%
Net Income
-557.6M
↓ 2.43%
Net Profit Margin
-143.84%
↑ 23.46%
Q4 FY22Q/Q Change
Revenue
380.1M
↓ 1.94%
Net Income
-445.3M
↓ 20.13%
Net Profit Margin
-117.16%
↑ 26.68%
Q1 FY23Q/Q Change
Revenue
447.8M
↑ 17.81%
Net Income
-348.4M
↓ 21.76%
Net Profit Margin
-77.81%
↑ 39.35%
Q2 FY23Q/Q Change
Revenue
595.3M
↑ 32.93%
Net Income
-381.1M
↑ 9.39%
Net Profit Margin
-64.03%
↑ 13.78%
Q3 FY23Q/Q Change
Revenue
781.3M
↑ 31.25%
Net Income
215.4M
↓ 156.52%
Net Profit Margin
27.57%
↑ 91.6%
Q4 FY23Q/Q Change
Revenue
634.4M
↓ 18.8%
Net Income
-367.6M
↓ 270.63%
Net Profit Margin
-57.94%
↓ 85.51%
FY18Y/Y Change
Total Assets
2.2B
↑ 114.98%
Total Liabilities
496.0M
↑ 36.93%
FY19Y/Y Change
Total Assets
1.6B
↓ 28.33%
Total Liabilities
633.9M
↑ 27.8%
FY20Y/Y Change
Total Assets
5.6B
↑ 247.38%
Total Liabilities
1.7B
↑ 173.14%
FY21Y/Y Change
Total Assets
8.6B
↑ 54.37%
Total Liabilities
2.4B
↑ 38.78%
FY22Y/Y Change
Total Assets
6.4B
↓ 26.22%
Total Liabilities
2.0B
↓ 16.94%
FY23Y/Y Change
Total Assets
5.8B
↓ 9.0%
Total Liabilities
2.2B
↑ 11.91%
Q3 FY22Q/Q Change
Total Assets
6.7B
↓ 8.84%
Total Liabilities
2.1B
↓ 0.23%
Q4 FY22Q/Q Change
Total Assets
6.4B
↓ 5.15%
Total Liabilities
2.0B
↓ 3.62%
Q1 FY23Q/Q Change
Total Assets
6.0B
↓ 6.62%
Total Liabilities
1.8B
↓ 9.84%
Q2 FY23Q/Q Change
Total Assets
5.7B
↓ 3.83%
Total Liabilities
1.9B
↑ 7.26%
Q3 FY23Q/Q Change
Total Assets
5.5B
↓ 3.56%
Total Liabilities
1.8B
↓ 8.73%
Q4 FY23Q/Q Change
Total Assets
5.8B
↑ 5.08%
Total Liabilities
2.2B
↑ 26.8%
FY18Y/Y Change
Operating Cash Flow
-547.7M
↓ 4395.15%
Investing Cash Flow
-637.6M
↑ 78.94%
Financing Cash Flow
1.7B
↑ 244.76%
FY19Y/Y Change
Operating Cash Flow
-750.3M
↑ 36.98%
Investing Cash Flow
554.2M
↓ 186.91%
Financing Cash Flow
85.7M
↓ 94.93%
FY20Y/Y Change
Operating Cash Flow
-1.3B
↑ 71.07%
Investing Cash Flow
-3.2B
↓ 671.74%
Financing Cash Flow
5.2B
↑ 5972.39%
FY21Y/Y Change
Operating Cash Flow
-1.3B
↑ 1.19%
Investing Cash Flow
640.7M
↓ 120.22%
Financing Cash Flow
3.6B
↓ 30.1%
FY22Y/Y Change
Operating Cash Flow
-1.5B
↑ 15.24%
Investing Cash Flow
1.1B
↑ 68.13%
Financing Cash Flow
-19.0M
↓ 100.52%
Q3 FY22Q/Q Change
Operating Cash Flow
-561.9M
↑ 47.89%
Investing Cash Flow
169.5M
↓ 74.27%
Financing Cash Flow
120.2M
↓ 783.97%
Q4 FY22Q/Q Change
Operating Cash Flow
-318.2M
↓ 43.37%
Investing Cash Flow
38.5M
↓ 77.26%
Financing Cash Flow
-110.4M
↓ 191.79%
Q1 FY23Q/Q Change
Operating Cash Flow
-563.8M
↑ 77.18%
Investing Cash Flow
67.8M
↑ 75.94%
Financing Cash Flow
-19.9M
↓ 82.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-293.9M
↓ 47.87%
Investing Cash Flow
67.8M
↑ 0.0%
Financing Cash Flow
166.1M
↓ 935.92%
Q3 FY23Q/Q Change
Operating Cash Flow
-78.2M
↓ 73.41%
Investing Cash Flow
-186.3M
↓ 374.74%
Financing Cash Flow
-76.8M
↓ 146.23%

Technicals Summary

Sell

Neutral

Buy

Beigene Ltd is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Beigene Ltd
Beigene Ltd
-6.37%
-13.43%
-41.6%
-55.57%
19.28%
Moderna, Inc.
Moderna, Inc.
-1.39%
41.81%
-19.31%
-38.71%
322.88%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.68%
13.74%
14.81%
80.88%
159.02%
Novo Nordisk A/s
Novo Nordisk A/s
-2.24%
29.49%
49.67%
240.51%
421.0%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.67%
10.39%
20.74%
84.71%
129.52%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Beigene Ltd
Beigene Ltd
NA
NA
0.0
-8.62
-0.22
-0.12
NA
33.83
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.77
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.13
26.13
1.46
45.02
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
48.36
48.36
2.4
3.34
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.17
29.17
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Beigene Ltd
Beigene Ltd
Buy
$15.6B
19.28%
NA
-35.86%
Moderna, Inc.
Moderna, Inc.
Buy
$41.3B
322.88%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.6B
159.02%
26.13
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$573.9B
421.0%
48.36
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$104.7B
129.52%
29.17
36.68%

Institutional Holdings

  • Baker Bros Advisors LP

    10.11%

  • Capital Research & Mgmt Co - Division 3

    6.06%

  • Hillhouse Capital Advisors, Ltd.

    4.95%

  • PRIMECAP Management Company

    4.77%

  • Baillie Gifford & Co Limited.

    3.70%

  • Temasek Holdings Ltd.

    2.88%

Corporate Announcements

  • Beigene Ltd Earnings

    Beigene Ltd’s price-to-earnings ratio stands at None

    Read More

Company Information

BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.

Organization
Beigene Ltd
Employees
10600
CEO
Mr. John V. Oyler
Industry
Health Technology

Discover More

FAQs